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Infection with the oncogenic types of human papillomavirus
(HPV) has been established as a main cause of high-grade cervical
intra-epithelial neoplasia (CIN 2–3), an immediate precursor of
cervical cancer (Lorincz et al, 1992; Cuzick et al, 1994). The time
lag between infection and development of invasive cervical cancer
is probably on average more than 15 years (Östör, 1993). Most
HPV infections clear spontaneously but a minority of infections,
especially of high-risk types, will persist and those are a major 
risk factor for development of CIN 2–3 (Ho et al, 1998). The risk
factors that determine whether HPV infection will be transient 
or become persistent as well as the risk factors that determine
progression from CIN to invasive cervical cancer are insufficiently
known.
Since certain risk factors for cervical cancer or CIN such as
smoking and oral contraceptive use have been reported to be asso-
ciated with HPV infection (Hildesheim et al, 1990; Butterworth
et al, 1992; Burger et al, 1993; Eluf-Neto et al, 1994; Ho et al,
1998; Kruger-Kjaer et al, 1998; Kwasniewska et al, 1998; Olsen
et al, 1998) this may have confounded the risk ratios. The transient
nature of HPV infections makes epidemiological studies of HPV
exposure as such difficult, since women currently negative for
HPV DNA may have been infected previously. However, the
serum antibody response to HPV capsids will persist on long-term
follow-up, even after HPV infection is no longer found (af
Geijersstam et al, 1998) and is a useful marker of life-time HPV
exposure (Olsen et al, 1997). As most previous studies have either
not taken HPV into account or only studied present infection, we
conducted a population-based case–control study of CIN 2–3 in
Northern Sweden, taking past and present HPV exposures into
account.
SUBJECTS AND METHODS
Study base
The Västerbotten county in Northern Sweden has 257 079 inhabi-
tants (1993). The population-based cervical screening programme
started in 1969 and all women resident in the county aged 25–59
years are invited by letter for screening every three years. The
participation rate is about 80%. The mean number of women
living in this area and aged between 25 and 59 years of age was
about 57 000.
Screening procedure
Cytologic samples, taken at regional health care centres by
midwives, were examined in the laboratory of Clinical Cytology,
Umeå University Hospital, the classification criteria being those
formulated by Koss (1979).
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Summary Smoking, nutrition, parity and oral contraceptive use have been reported as major environmental risk factors for cervical cancer.
After the discovery of the very strong link between human papillomavirus (HPV) infection and cervical cancer, it is unclear whether the
association of these environmental factors with cervical cancer reflect secondary associations attributable to confounding by HPV, if they are
independent risk factors or whether they may act as cofactors to HPV infection in cervical carcinogenesis. To investigate this issue, we
performed a population-based case–control study in the Västerbotten county of Northern Sweden of 137 women with high-grade cervical
intra-epithelial neoplasia (CIN 2–3) and 253 healthy age-matched women. The women answered a 94-item questionnaire on diet, smoking,
oral contraceptive use and sexual history and donated specimens for diagnosis of present HPV infection (nested polymerase chain reaction
on cervical brush samples) and for past or present HPV infections (HPV seropositivity). The previously described protective effects of dietary
micronutrients were not detected. Pregnancy appeared to be a risk factor in the multivariate analysis (P < 0.0001). Prolonged oral
contraceptive use and sexual history were associated with CIN 2–3 in univariate analysis, but these associations lost significance after taking
HPV into account. Smoking was associated with CIN 2–3 (odds ratio (OR) 2.6, 95% confidence interval (CI) 1.7–4.0), the effect was dose-
dependent (P = 0.002) and the smoking-associated risk was not affected by adjusting for HPV, neither when adjusting for HPV DNA (OR 2.5,
CI 1.3–4.9) nor when adjusting for HPV seropositivity (OR 3.0, CI 1.9–4.7). In conclusion, after taking HPV into account, smoking appeared
to be the most significant environmental risk factor for cervical neoplasia. © 2000 Cancer Research Campaign
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Referral group
Between October 1993 and December 1995, 254 women with 
a pathological cervical smear, referred for colposcopy in
Västerbotten county were asked to participate. One hundred and
seventy-four women were referred from the population-based
cervical screening programme and 76 because of smears taken
outside the programme. They were referred to any of the three
hospitals in Västerbotten county: Umeå University Hospital,
Skellefteå Community Hospital or Lycksele Community Hospital.
Four of the referred women refused to participate in the study, and
the remaining 250 were enrolled. One hundred and thirty-seven of
these women were finally diagnosed with CIN 2–3. The final diag-
nosis was based on blinded histopathological re-classification by
an experienced pathologist of stored archival biopsy specimens
(130 cases) and for seven cases where an archival biopsy was not
available, on a blinded reclassification of the cytological archival
specimen. The mean age was 37.2 years (range 21–58).
Screening group
A group of women who were invited by letter for screening in the
organized programme were asked by an additional enclosed letter
to attend the study. The women were selected randomly from the
population registry and matched to the referrals 1:1 for age (±3
years) and area of residence. From October 1995 until March
1996, out of 2191 invited women, 871 were asked to participate
and 320 accepted. In order to find out the reason 63% did not
accept the invitation, a randomly selected subgroup of 50 of these
women was interviewed by telephone by the same investigator.
Two were not interested to participate in the screening programme
at all. The other 48 women had recently seen or intended to see a
doctor or midwife for screening and did not want to participate
because of inconvenience.
Sampling procedures
In January 1995, the organized screening programme switched
cervical sampling device to Cervex brush (Cortec Medical AB,
Malmö, Sweden) that permits collecting cell samples from both
ecto- and endocervix. The 114 samples that were taken before that
time were taken with a cotton-tipped pin in the endocervix and a
wooden spatula from the ectocervix and posterior fornix. Before
colposcopic examination, a sample for HPV DNA was taken from
the endocervix by a rotary motion with a Cytobrush (Medscand,
Malmö, Sweden) for detection of cervical HPV DNA by nested
polymerase chain reaction (PCR) with consensus primers and
type-specific primers for HPV 11, 16, 18 and 33. The HPV sample
was stored in physiologic saline containing 10 mM Tris–HCl
buffer, pH 7.8 and kept at –70°C until analysis. If the colposcopic
examination was normal an annual follow-up was arranged.
In the screening population, all women were examined by the
same physician. Samples for cytomorphology and HPV DNA
detection was taken and stored in the same manner as for referrals
after January 1995. Although the sample for HPV DNA detection
was taken identically for all cases and controls, the fact that the
114 cases sampled in 1993–1994 had had their previous Pap smear
taken with a different utensil might have introduced differential
misclassification bias. This was investigated by comparing the
HPV results for cases sampled before and after January 1995, and
no differences were found (Kjellberg et al, 1998).
Questionnaire
The women answered a questionnaire concerning dietary habits,
tobacco use, health conditions, psychosocial situation and an 11-
item questionnaire about sexual and reproductive history.
The food frequency part included 84 items with an increasing
nine-level scale, ranging from never eaten to eaten four or more
times per day and the respondents were asked to report their usual
intake of food during the last year. A standardized portion size
adjusted for sex and age was used.
The energy and nutrients contents were calculated using the
database from the National Food Administration (Bergström et al,
1991). The reported frequencies of consumption were converted
into number of intakes per day and the total intake of energy and
nutrients was estimated.
Missing answers in the food groups with several alternative
items and where one of the alternatives was eaten frequently, such
as milk products and types of fats for bread, were interpreted as
being never eaten.
The food frequency questionnaire has been extensively vali-
dated previously (Johansson et al, 1994; submitted).
Analysis
HPV PCR analysis, HPV typing and antibody analysis were
carried out as described previously (Kjellberg et al, 1998).
Statistical analysis
Using the Statistical Package for the Social Sciences (SPSS)
program software, conditional logistic regression analysis was
used to calculate the odds ratios (OR) with 95% confidence
interval (CI).
RESULTS
A total of 543 women answered the food questionnaire and 448
were eligible as cases (histological diagnosis of CIN 2–3) or
controls (normal cytology). Nineteen women had too many missed
answers (> 6 items) and five reported an unrealistic energy intake
(<500 kcal or > 3500 kcal) and were therefore excluded. Five
hundred and forty women had answered the questionnaire about
smoking habits and 468 were eligible as cases or controls. The
questionnaire about sexual history was answered by 556 women of
which 480 were eligible. The distribution of dietary intake among
women with normal cervical cytology and with CIN 2–3 is
presented in Table 1. Drinking boiled coffee and a high intake of
dairy products were the only significant positive associations. The
point estimates changed only marginally after taking HPV and
smoking into account (data not shown). A reduced risk associated
with tea drinking and increased intake of vegetable fibres was not
significant after adjusting for HPV DNA and smoking (Table 1).
A prolonged period of oral contraceptive (OC) use (more than
5 years) was associated with an increased risk for CIN 2–3
(P < 0.05), but this risk disappeared after adjustment for HPV,
smoking and age (Table 2). Since OC use has been postulated to
act via influencing the folate status (Butterworth et al, 1982;
Harper et al, 1994) the possibility of an interaction between OC
use and folate status was investigated. There was no OC-associ-
ated risk for CIN 2–3, neither among women with high, nor among
women with low, folate intake (data not shown).
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Table 1 Odds ratios of CIN 2–3 according to dietary intake of fat and fibre from various sources and selected vitamins
Normal CIN 2–3 Total OR Adj ORa Adj ORb
number
Fat total (quartiles)
g day–1 < 43.7 60 (75%) 20 (25%) 80 1.0 (n = 321) 1.0 (n = 316) 1.0 (n = 311)
43.7 ≤ 55.5 g day–1 60 (75%) 20 (25%) 80 1.0 (0.5–2.0) 0.6 (0.2–2.2) 1.0 (0.4–2.1)
55.5 ≤ 70.9 g day–1 61 (75%) 20 (25%) 81 1.0 (0.5–2.0) 0.3 (0.1–1.2) 0.8 (0.3–1.7)
day–1 ³ 70.9 g  53 (66%) 27 (34%) 80 1.5 (0.8–3.0) 0.9 (0.3–3.2) 1.5 (0.7–3.5)
Missing 98 29 127
P for trend 0.24 0.71 0.45
Fat, saturated (quartiles)
g day–1 < 18.5 60 (72%) 23 (28%) 83 1.0 (n = 332) 1.0 (n = 326) 1.0 (n = 321)
18.5 ≤ 24.3 g day–1 62 (75%) 21 (25%) 83 0.9 (0.4–1.8) 1.0 (0.3–3.2) 0.7 (0.3–1.6)
24.3 ≤ 31.2 g day–1 68 (81%) 16 (19%) 84 0.6 (0.3–1.3) 0.7 (0.2–2.1) 0.5 (0.2–1.2)
day–1 ³ 31.2 g  53 (65%) 29 (35%) 82 1.4 (0.7–2.8) 1.2 (0.4–3.7) 1.3 (0.6–2.9)
Missing 89 27 116
P for trend 0.45 0.94 0.65
Fat, monounsaturated (quartiles)
g day–1 < 15.5 63 (76%) 20 (24%) 83 1.0 (n = 333) 1.0 (n = 327) 1.0 (n = 322)
15.5 ≤ 19.6 g day–1 61 (75%) 20 (25%) 81 1.0 (0.5–2.1) 0.8 (0.3–2.6) 1.0 (0.4–2.2)
19.6 ≤ 24.7 g day–1 63 (74%) 22 (26%) 85 1.1 (0.5–2.2) 0.7 (0.2–2.2) 1.0 (0.4–2.1)
g day–1³ 24.7   57 (68%) 27 (32%) 84 1.5 (0.8–2.9) 0.9 (0.3–2.9) 1.4 (0.6–3.2)
Missing 88 27 115
P for trend 0.24 0.85 0.42
Fat, polyunsaturated (quartiles)
g day–1 < 5.93 58 (71%) 24 (29%) 82 1.0 (n = 329) 1.0 (n = 324) 1.0 (n = 319)
5.93 ≤ 7.67 g day–1 66 (81%) 16 (19% 82 0.6 (0.3–1.2) 0.3 (0.1–1.1) 0.5 (0.2–1.1)
7.67 ≤ 1 9.74 g day– 57 (69%) 26 (31%) 83 1.1 (0.6–2.1) 0.9 (0.3–2.7) 0.8 (0.4–1.7)
day–1 ³ 9.74 g  58 (71%) 24 (29%) 82 1.0 (0.5–2.0) 0.9 (0.3–2.7) 1.0 (0.4–2.1)
Missing 93 26 119
P for trend 0.59 0.90 0.82
Fibre, total (quartiles)
g day–1 < 11.55 65 (71%) 26 (29%) 91 1.0 (n = 366) 1.0 (n = 361) 1.0 (n = 356)
11.55 ≤ 14.63  g day–1 66 (72%) 26 (28%) 92 1.0 (0.5–1.9) 0.5 (0.1–1.5) 1.2 (0.6–2.5)
14.63 ≤ 19.13 g day–1 69 (75%) 23 (25%) 92 0.8 (0.4–1.6) 0.4 (0.1–1.3) 1.1 (0.5–2.2)
g day–1³ 19.13   71 (78%) 20 (22%) 91 0.7 (0.4–1.4) 1.6 (0.5–5.2) 1.2 (0.6–2.6)
Missing 61 21 82
P for trend 0.26 0.58 0.75
Cereal fibre (quartiles)
g day–1 < 4.23 79 (77%) 24 (23%) 103 1.0 (n = 412) 1.0 (n = 405) 1.0 (n = 401)
4.23 ≤ 6.72 g day–1 69 (67%) 34 (33%) 103 1.6 (0.9–3.0) 0.6 (0.2–1.7) 1.7 (0.9–3.3)
6.72 ≤ 9.49 g day–1 75 (73%) 28 (27%) 103 1.2 (0.6–2.3) 0.6 (0.2–1.7) 1.3 (0.7–2.7)
g day–1 ³ 9.49 84 (82%) 19 (18%) 103 0.7 (0.4–1.5) 0.9 (0.3–2.5) 1.0 (0.5–2.2)
Missing 25 11 36
P for trend 0.29 0.79 0.96
Fruit & berry fibre (quartiles)
g day–1 < 1.54 71 (65%) 38 (35%) 109 1.0 (n = 439) 1.0 (n = 431) 1.0 (n = 428)
1.54 ≤ 2.43 g day–1 88 (78%) 25 (22%) 113 0.5 (0.3–1.0) 0.6 (0.2–1.6) 0.6 (0.3–1.1)
2.43 ≤ 4.76 g day–1 80 (73%) 29 (27%) 109 0.7 (0.4–1.2) 1.4 (0.5–3.8) 0.9 (0.5–1.7)
g day–1 ³ 4.76 85 (79%) 23 (21%) 108 0.5 (0.3–0.9) 1.3 (0.5–3.5) 0.9 (0.4–1.7)
Missing 8 1 9
P for trend 0.06 0.41 0.92
Vegetable fibre (quartiles)
g day–1 < 0.678 71 (65%) 38 (35%) 109 1.0 (n = 436) 1.0 (n = 429) 1.0 (n = 425)
0.678 ≤ 1.139 g day–1 79 (72%) 30 (28%) 109 0.8 (0.4–1.3) 0.5 (0.2–1.3) 0.8 (0.4–1.4)
1.139 ≤ 1.90 g day–1 86 (79%) 23 (21%) 109 0.5 (0.3–0.9) 0.5 (0.2–1.4) 0.5 (0.3–1.1)
g day–1 ³ 1.90 86 (79%) 23 (21%) 109 0.5 (0.3–0.9) 1.0 (0.4–2.6) 0.6 (0.3–1.2)
Missing 10 2 12
P for trend 0.01 0.85 0.09
Vitamin C (quartiles)
mg day–1 < 50.7 73 (72%) 28 (28%) 101 1.0 (n = 404) 1.0 (n = 398) 1.0 (n = 494)
50.7 ≤ 79.1 mg day–1 79 (78%) 22 (22%) 101 0.7 (0.4–1.4) 0.1 (0.1–0.5) 0.8 (0.4–1.6)
79.1 ≤ 110.2 mg day–1 72 (71%) 29 (29%) 101 1.1 (0.6–1.9) 0.7 (0.2–2.2) 1.1 (0.6–2.3)
mg day–1 ³ 110.2 76 (75%) 25 (25%) 101 0.9 (0.5–1.6) 0.6 (0.2–1.7) 1.1 (0.6–2.2)
Missing 32 12 44
P for trend 0.92 0.91 0.58
Folate (quartiles)
mg day–1 < 139 55 (69%) 25 (31%) 80 1.0 (n = 322) 1.0 (n = 317) 1.0 (n = 312)
139 ≤ 1 173.6 mg day– 63 (78%) 18 (22%) 81 0.6 (0.3–1.3) 0.3 (0.1–1.2) 0.6 (0.3–1.4)
173.6 ≤ 214 mg day–1 57 (70%) 24 (30%) 81 0.9 (0.5–1.8) 0.5 (0.1–1.5) 0.7 (0.3–1.6)
mg day–1 ³ 214 61 (76%) 19 (24%) 80 0.7 (0.3–1.4) 1.4 (0.4–4.8) 1.0 (0.4–2.1)
Missing 90 36 126
P for trend 0.50 0.62 0.95
aAdjusted odds ratios for HPV DNA, smoking and age. bAdjusted odds ratios for HPV seropositivity, smoking and age.A significant risk for CIN 2–3 was found for an early age at first
coitus and for the number of lifetime sexual partners, but after
adjusting for HPV, smoking and age this association disappeared
(Table 2). Pregnancy was not a risk factor in the crude analysis, but
having been pregnant was revealed as a strong risk factor in the
adjusted analysis (Table 2).
Smoking history was associated with a risk for CIN 2–3 and
adjusting for HPV did not affect the point estimate. Stratified
analysis of the effect of covarying risk factors among HPV-posi-
tive women only has been proposed by Schiffman et al, (1993) as a
preferred analysis method instead of adjusting for HPV. Such
analysis was, however, not meaningful because of too few women
Risk factors for HPV in high grade CIN 1335
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Table 2 Sexual history and their associations with the risk of CIN 2–3
Normal CIN 2–3 Total number OR Adj ORa Adj ORb
Age of sexual debut
> 20 45 (90%) 5 (10%) 50 1.0 (n = 478) 1.0 (n = 455) 1.0 (n = 455)
15–20 284 (72%) 113 (28%) 397 3.6 (1.4–9.2) 5.3 (0.8–37.1) 3.2 (0.9–10.8)
< 15 18 (58%) 13 (42%) 31 6.5 (2.0–20.9) 2.9 (0.3–26.5) 3.1 (0.7–13.4)
Never 2 0 2
Missing 0 0 0
P for trend 0.001 0.79 0.19
No. of lifetime sexual
partnersc
0–1 61 (92%) 5 (8%) 66 1.0 (n = 479) 1.0 (n = 456) 1.0 (n = 456)
2–5 165 (70%) 71 (30%) 236 5.2 (2.0–13.6) 2.2 (0.6–8.1) 2.7 (1.0–7.3)
> 5 123 (70%) 54 (30%) 177 5.4 (2.0–14.1) 1.1 (0.3–4.3) 1.9 (0.7–5.3)
Missing 0 1 1
P for trend 0.004 0.34 0.96
Use of OC
Never 61 (84%) 12 (16%) 73 1.0 (n = 480) 1.0 (n = 457) 1.0 (n = 457)
< 1 year 58 (76%) 18 (24%) 76 1.5 (0.7–3.5) 1.2 (0.3–4.8) 1.5 (0.6–3.9)
1–5 years 124 (76%) 40 (24%) 164 1.6 (0.8–3.3) 1.1 (0.3–3.5) 1.4 (0.6–3.3)
> 5 years 106 (64%) 61 (36%) 167 2.9 (1.5–5.9) 1.6 (0.5–5.3) 2.1 (0.9–4.9)
Missing 0 0 0
P for trend 0.02 0.50 0.16
Pregnancy
Never 84 (75%) 28 (25%) 112 1.0 (n = 469) 1.0 (n = 446) 1.0 (n = 447)
Ever 259 (72%) 98 (28%) 357 1.1 (0.7–1.8) 4.5 (1.6–12.8) 2.5 (1.3–4.9)
Missing 6 5 11
aAdjusted odds ratios for HPV DNA, smoking and age. bAdjusted odds ratios for HPV seropositivity, smoking and age. cThe data on number of lifetime sexual
partners has also been published in Kjellberg et al (1999).
Table 3 Association between three measures of smoking and CIN 2–3 in individuals positive for HPV DNA and HPV Capsid antibodies respectively
Normal CIN 2–3 Total OR Adj ORa Adj ORb
number
Never-smoker & party-smoker 215 (82%) 47 (18%) 262 1.0 (n = 468) 1.0 (n = 461) 1.0 (n = 459)
Past-smoker & smoker 131 (64%) 75 (36%) 206 2.6 (1.7–4.0) 2.5 (1.3–4.9) 3.0 (1.9–4.7)
Missing 0 0 0
Never-smoker & party-smoker 215 (82%) 47 (18%) 262 1.0 (n = 468) 1.0 (n = 461) 1.0 (n = 459)
Past-smoker 56 (68%) 26 (32%) 82 2.1 (1.2–3.7) 2.3 (1.0–5.6) 2.8 (1.5–5.2)
Smoker 75 (61%) 49 (39%) 124 3.0 (1.8–4.8) 2.6 (1.2–5.6) 3.1 (1.8–5.2)
Missing 0 0 0
Years of smoking
< 1 year 215 (82%) 47 (18%) 262 1.0 (n = 464) 1.0 (n = 457) 1.0 (n = 455)
1–9 years 16 (64%) 9 (36%) 25 2.6 (1.1–6.2) 3.5 (0.9–13.8) 3.1 (1.2–7.8)
³ 10 years 114 (64%) 63 (36%) 177 2.5 (1.6–3.9) 2.3 (1.2–4.6) 2.8 (1.7–4.6)
Missing 1 3 4
Number of cigarettes/day
Never-smoker & party-smoker 215 (82%) 47 (18%) 262 1.0 (n = 468) 1.0 (n = 461) 1.0 (n = 459)
Past-smoker 56 (68%) 26 (32%) 82 2.1 (1.2–3.7) 2.3 (1.0–5.9) 2.8 (1.5–5.1)
Smokers 1–4 14 (74%) 5 (26%) 19 1.6 (0.6–4.8) 0.5 (0.1–1.9) 1.9 (0.6–6.0)
5–14 46 (67%) 23 (33%) 69 2.3 (1.3–4.1) 3.2 (1.2–8.4) 2.4 (1.3–4.6)
³ 15 15 (42%) 21 (58%) 36 6.4 (3.1–13.3) 5.8 (1.7–19.4) 6.0 (2.7–13.3)
Missing 0 0 0
P for trend < 0.001 < 0.001 < 0.001
aAdjusted odds ratios for HPV-DNA and age. bAdjusted odds ratios for HPV-Capsid and age.in the reference category. There was a dose–effect relationship
with the number of cigarettes smoked per day (Table 3). Possible
interaction between HPV16 and smoking was explored using the
jointly negative as the reference category (Olsen et al, 1998).
Smoking increased the point estimate of the CIN 2–3 risk both
among HPV DNA positive and negative women and both among
HPV seropositive and seronegative women, but there was no
evidence of interaction (Table 4).
DISCUSSION
This is one of only few population-based studies of the CIN 2–3 risk
associated with major environmental risk factors such as smoking,
diet and oral contraceptives that has taken HPV exposure into
account. Earlier studies have commonly been contradictory.
Micronutrients such as folic acid, vitamins A, E, C and b-carotene
have in some studies shown a protective effect on cervical cancer
and CIN (Cuzick et al, 1990; Slattery et al, 1990; Herrero et al,
1991; Liu et al, 1993) and some other studies not (Ziegler et al,
1991; Palan et al, 1998; Wideroff et al, 1998). In our study, we could
not show any protective effect of these dietary components and risk
for CIN 2–3, not even before adjustment for HPV. We measured
food intake and not serum levels of micronutrients, but neither this
study nor some of the studies that also analysed serum levels of
micro-nutrients could show any association to CIN 2–3
(Butterworth et al, 1992; Ho et al, 1998). Oral contraceptive pill
intake has been postulated to induce a local folic acid deficiency and
interfere with DNA synthesis, repair or somehow alter the suscepti-
bility of cells to oncogenic viruses or chemical carcinogens and
therefore be a risk factor for CIN (Butterworth et al, 1982; Harper et
al, 1994). We found no association of folate intake with CIN 2–3 in
the first place and also did not detect any interaction between folate
intake and OC use. The risk associated with prolonged OC use was
entirely explained by taking HPV into account.
The dietary associations found in this study (increased risk asso-
ciated with boiled coffee and with high intake of dairy products)
have not been consistently found in previous studies and the possi-
bility exists that they may be chance associations attributable to
multiple hypothesis testing. Further studies would be needed to
evaluate the consistency of these risks. As earlier shown, retro-
spective collection of dietary information can lead to misclassifi-
cation and to biased estimates as compared to prospectively
collected dietary information, i.e. ‘recall bias’ (Michaelsson et al,
1996).
In the present study, cofactors were studied taking both HPV
DNA presence (present/persistent infection) and HPV seroposi-
tivity (cumulative exposure) into account. This is intended to
allow distinguishing between cofactors independent of HPV (not
affected by HPV adjustments), cofactors confounded by risk of
HPV exposure (eliminated both by adjusting for HPV seroposi-
tivity and for HPV DNA) and cofactors that determine whether
HPV is cleared or becomes persistent (eliminated by adjusting for
HPV DNA, not affected by adjusting for HPV seropositivity).
However, HPV seropositivity is not completely sensitive (esti-
mated at 50–70% sensitivity; Kjellberg et al, 1999) and attenuation
but not elimination of risks after adjusting for HPV seropositivity
may also reflect residual confounding.
Sexual history is an established risk factor for CIN and cervical
cancer. In a previous paper, we have found that HPV-infection
explained this association and that sexual history per se thus was
not a risk factor (Kjellberg et al, 1999). In this study we detected
the well known association between early age of sexual debut and
risk for CIN, but again this association lost significance after
adjusting for HPV infection.
Parity has repeatedly been found to be a cervical cancer risk
factor (Schiffmann and Brinton, 1995) also after taking HPV DNA
into account (Schiffmann et al, 1993). Causal models that have
been proposed are trauma to the cervix or hormonal effects
1336 L Kjellberg et al
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Table 4a Joint effect of smoking and HPV seropositivity
Normal CIN 2–3 OR Adj. ORa Adj. ORb
HPV seronegative
Never-smoker 134 (92%) 11 (8%) 1.0 (n = 459) 1.0 (n = 459) 1.0 (n = 452)
Ever-smoker 77 (73%) 29 (27%) 4.6 (2.2–9.7) 5.6 (2.6–12.0) 5.2 (1.8–15.2)
HPV seropositive
Never-smoker 79 (70%) 34 (30%) 5.2 (2.5–10.9) 5.2 (2.5–11.0) 4.6 (1.6–12.9)
Ever-smoker 53 (56%) 42 (44%) 9.7 (4.6–20.2) 10.5 (5.0–22.4) 7.2 (2.5–20.6)
Missing 3 6
aAdjusted odds ratios for age. bAdjusted odds ratios for HPV DNA and age.
Table 4b Joint effect of smoking and HPV DNA positivity
Normal CIN 2–3 OR Adj. ORa Adj. ORb
HPV DNA negative
Never-smoker 199 (98%) 5 (2%) 1.0 (n = 461) 1.0 (n = 461) 1.0 (n = 452)
Ever-smoker 116 (91%) 12 (9%) 4.1 (1.4–12.0) 4.3 (1.5–12.7) 3.8 (1.3–11.2)
HPV DNA positive
Never-smoker 14 (26%) 40 (74%) 114 (39–333) 110 (37–326) 93 (31–280)
Ever-smoker 13 (17%) 62 (83%) 190 (65–553) 189 (65–552) 186 (62–556)
Missing 4 3
aAdjusted odds ratios for age. bAdjusted odds ratios for HPV seropositivity and age.(Schiffman and Brinton, 1995). Since very few women in our
study were multiparous, we investigated a possible effect of preg-
nancy. There was no association in the crude analyses, but a strong
association was revealed after taking HPV into account. Our study
thus suggests that pregnancy may both increase the risk for CIN
2–3 and protect against HPV infection. Previous literature on the
interaction between HPV infection and pregnancy has not been
consistent and further studies on the subject would seem to be
warranted.
The effects of smoking have been well studied and show a
strong association to CIN and cervical cancer (Cuzick et al, 1990;
Winkelstein, 1990; Phillips and Smith, 1994; Ho et al, 1998;
Kruger-Kjaer et al, 1998; Olsen et al, 1998). Chemical carcinogens
in tobacco, such as cotinine and nicotine, probably exert a mito-
genic effect by activating carcinogenic nitrosamines and causing
DNA damage and also may impair the local immune defence in
the cervical epithelium. However, the fact that smoking as a
behaviour in some populations is associated with a lifestyle with
increased risk for HPV infection has suggested that the association
seen with smoking may be due to residual confounding from HPV
or other sexually transmitted pathogens (Winkelstein, 1990; Ho et
al, 1998). The fact that the significant excess risk for CIN 2–3
associated with smoking was not reduced by adjustment for HPV
indicates that smoking does indeed have a causal association with
CIN 2–3. This is also supported by reports indicating that smoking
cessation facilitates regression of CIN (Szarewski et al, 1996).
Whether smoking is an entirely independent risk factor or works as
a risk modifier of HPV exposure could not be disclosed in the
present study.
In summary, we found little evidence that variations within the
normal Swedish food intake influences the risk for cervical
neoplasia, nor that oral contraceptive use per se influences this
risk. By contrast, the association with smoking was dose-depen-
dent and could not be explained by confounding by HPV. The
present study supports the concept that the risk associated with
smoking is causal.
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